NICE recommends apixaban but rejects roflumilast

New recommendations from the national body have been released regarding Eliquis and Daxas.

Eliquis is recommended by NICE for prevention of venous thromboembolism following hip replacement surgery | SCIENCE PHOTO LIBRARY

Eliquis approved

The National Institute for Health and Care Excellence (NICE) has recommended that apixaban (Eliquis) be made available on the NHS for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.

The recommended dosage of apixaban is 2.5mg twice daily. The initial dose should be taken 12–24 hours after surgery. Treatment should be continued for 32–38 days following hip surgery or for 10–14 days following knee surgery.

Daxas rejected    

NICE rejected the use of roflumilast (Daxas) for the management of severe chronic obstructive pulmonary disease (COPD). The PDE4 inhibitor is recommended only as part of a clinical study for adults with severe COPD associated with chronic bronchitis with a history of frequent exacerbations, as an add-on to bronchodilator treatment.  

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head